脉血康胶囊联合甲氨蝶呤治疗类风湿性关节炎的临床观察

目的：观察脉血康胶囊联合甲氨蝶呤治疗类风湿性关节炎（RA）的临床疗效和安全性。方法：将65例RA患者按随机数字表法分为两组。对照组（30例）患者给予甲氨蝶呤10mg，每周1次；治疗组（35例）患者在对照组治疗基础上加用脉血康胶囊1000mg，tid。两组疗程均为30d。观察两组患者临床疗效和临床症状、体征及实验室指标改善情况，以及治疗过程中不良反应发生情况。结果：治疗后，治疗组患者的总有效率为91．4％，显著高于对照组（70．0％），两组比较差异有统计学意义（P〈0．05）；治疗组患者在肿胀关节数、压痛关节数、红细胞沉降率、C反应蛋白、血小板计数等方面的改善均显著优于对照组，两组比较差异有统计学意义（P〈0．05）；两组患者不良反应发生率比较，差异无统计学意义（P〉0．05）。结论：脉血康胶囊联合甲氨蝶呤治疗RA疗效较好，可显著改善RA患者的临床症状以及实验室指标，且不增加不良反应的发生。

Clinical Observation of Maixuekang Capsules Combined with Methotrexate in the Treatment of Rheumatoid Arthritis

OBJECTIVE：To observe the clinical efficacy and safety of Maixuekang capsules combined with methotrexate in the treatment of rheumatoid arthritis （RA）. METHODS： 65 RA patients were randomly divided into 2 groups. Control group （n= 30） was given methotrexate 10 mg, once a week. Treatment group （n=35） was additionally given Maixuekang capsules 1 000 mg, 3 times a day, on the basis of control group. Clinical symptoms and signs, laboratory index were observed in 2 groups after 30 days treatment, and clinical efficacies were compared. The adverse drug reaction were recorded and observed during treatment. RESULTS： The total effective rate of treatment group was 91.4%, which was significantly higher than in control group （70.0%） ; there was statistical significance （P〈0.05）. The improvement of swollen joint counts, tender joint count, erythrocyte sedimentation rate, C-reactive protein and blood platelet count in treatment group were significantly better than in control group; there were statis- tical significances （P〈0.05）. There was no statistical significance in the incidence of adverse drug reaction between 2 groups （P〉 0.05）. CONCLUSIONS：Therapeutic efficacy of hirudin combined with methotrexate is better than methotrexate alone in the treatment of RA and improve clinical symptoms and labortaory index of RA patients without side effects.